Jointown Pharmaceutical Group Co Ltd
SSE:600998
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (0.7), the stock would be worth ¥6.16 (19% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.6 | ¥5.17 |
0%
|
| 3-Year Average | 0.7 | ¥6.16 |
+19%
|
| 5-Year Average | 0.7 | ¥6.37 |
+23%
|
| Industry Average | 2.1 | ¥19.44 |
+276%
|
| Country Average | 1.9 | ¥18.14 |
+251%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
26.1B CNY | 0.6 | 9.4 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
100.1B USD | 5 | 23.1 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.1B USD | 3.2 | 36.4 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.5B USD | 3.2 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
46.1B USD | 3.2 | 27.7 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.3B AUD | 4.8 | 35.5 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.4B CNY | 0.6 | 11.1 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 1.2 | 21.5 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.5B CNY | 2.1 | 20.6 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 4.7 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.6B HKD | 0 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.9 |
| 70th Percentile | 3.4 |
| Max | 1 129 391.6 |
Other Multiples
Jointown Pharmaceutical Group Co Ltd
Glance View
In the sprawling landscape of the Chinese pharmaceutical industry, Jointown Pharmaceutical Group Co. Ltd. has emerged as a significant player, knitting together a vast network that facilitates the distribution of pharmaceutical products across the nation. Founded in 1999 and headquartered in Wuhan, Jointown has adeptly navigated the complexities of China's healthcare demands, becoming the country's largest privately-owned pharmaceutical wholesaler. The company’s operations span the procurement, distribution, and sale of a myriad of pharmaceutical products, medical devices, and healthcare supplies, effectively serving hospitals, clinics, and pharmacies through its extensive logistics and distribution channels. By leveraging cutting-edge technology to enhance its supply chain efficiency, Jointown ensures timely delivery and accessibility of medicines across urban and rural areas, thereby playing a pivotal role in supporting China's healthcare system. Jointown’s business model capitalizes on its robust logistical capabilities and comprehensive distribution network, which underpin its revenue streams. Through strategic partnerships with numerous domestic and international manufacturers, the company offers an impressive portfolio of pharmaceutical and healthcare products, maintaining a careful balance between proprietary and third-party offerings. This diversity in product offerings not only stabilizes its revenue base but also positions Jointown favorably in a highly competitive market. By continually expanding its e-commerce platforms and digital interfaces, the company fosters direct interaction with consumers, enhancing customer engagement and opening new revenue avenues. In essence, Jointown's prowess lies in its ability to integrate traditional distribution methods with innovative digital solutions, ensuring the company’s sustained growth and relevance in the ever-evolving pharmaceutical industry.